Last updated on October 2017

Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer


Brief description of study

This is a Phase 1b/2a, open-label, multi-center study to evaluate the safety and tolerability, anti-tumor activity, and immunogenicity of MEDI0457 (also known as INO 3112) a HPV DNA vaccine in combination with durvalumab (also known as MEDI4736) which is a human monoclonal antibody directed against PD-L1, which blocks the interaction of PD-L1 with PD-1 and CD80. An initial three to 12 patients (Safety Analysis Run-in patients) will be enrolled and assessed for safety before additional patients are enrolled. The initial safety analysis run-in patients along with an approximate total of 50 patients with human papilloma virus associated recurrent or metastatic head and neck squamous cell cancer will be enrolled in this study and evaluated also for anti-tumor efficacy to MEDI0457 in combination with durvalumab.

Clinical Study Identifier: NCT03162224

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

AstraZeneca Clinical Study Information Center

Research Site
Atlanta, GA United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
The Bronx, NY United States
  Connect »

AstraZeneca Clinical Study Information Center

Research Site
Philadelphia, PA United States
  Connect »